Outcomes of a multidisciplinary partnership to improve cardiac wellness: An opportunity for pharmacists

Consultant Pharmacist

Volumn 25, Issue 2, 2010, Pages 105-116

  Miller, Susan W ^a   Darsey, Edress ^b   Heard, Thomas J ^b   Williams, Jill ^b   Kelly, Maureen ^c   Norman, Arnisha ^c   Ter Riet, Linh B ^b  

^a MERCER UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c Atlanta Regional Commission   (United States)

Author keywords

Ambulatory senior population; Cardiovascular risk profile; Cholesterol management; Coronary heart disease; Outcomes; Partnership; Wellness

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HEART FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT PARTICIPATION; PHARMACIST;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; CHOLESTEROL; COOPERATIVE BEHAVIOR; CORONARY DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERDISCIPLINARY COMMUNICATION; LIFE STYLE; MALE; MASS SCREENING; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PHARMACISTS; PROFESSIONAL ROLE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 77749289785     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2010.105     Document Type: Article

References (27)

1. Consensus Conference. Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080-6.
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
4. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333-445.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
7. Grundy SM, Cleeman JI, Merz NB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
8. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100:605-10.
9. Hoerger TJ, Bala MV, Bray JW et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. [National Center for Health Statistics: National Health and Nutrition Examination Survey (NHANES III)]. Am J Cardiol 1998;82:61-5.
10. Cupples LA, D'Agostine RB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. In Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease, Section 34. Bethesda, MD: National Heart, Lung, and Blood Institute; 1987:publication no. (NIH) 87-2703.
11. Abbott RD, McGee D. The Probability of Developing Certain Cardiovascular Disease in Eight Years of Specified Values of Some Characteristics: The Framingham Study, Section 37. Bethesda, MD: National Heart, Lung, and Blood Institute; 1987.
12. Wolf PA, D'Agostine RB, Balangerr AJ et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-8.
13. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
14. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;360:7-22.
16. Shepard J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
17. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. J Am Med Assoc 1998;279:1615-22.
18. Sever P, Dahlof B, Poulter N et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). Lancet 2003;361:1149-58.
19. Cannon CP, Braunwald E, McCabe CH et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 2004;350:1495-504.
20. Grundy SM, Cleeman JI, Merz CNB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
21. Larosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1-11.
22. Tsuyuki RT, Johnson JA, Teo KT et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.
23. Tsuyuki RT, Olson KL, Dubyk AM et al. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Am J Med 2004;116:130-3.
24. Charrois TL, Johnson JA, Blitz S et al. Relationship between number, timing, and type of pharmacist interventions and patient outcomes. Am J Health Syst Pharm 2005;62:1798-801.
25. Yamada C, Johnson JA, Robertson P et al. Long term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Pharmacotherapy 2005;25:110-5.
26. Olson KL, Bungard TJ, Tsuyuki RT. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy 2001;21:807-17.
27. Granner ML, Sharpe PA. Evaluating community coalition characteristics and functioning: a summary of measurement tools. Health Edu Research 2004;19:514-32.